Rachel J. Church, Gerd A. Kullak‐Ublick, Jiri Aubrecht, Herbert L. Bonkovsky, Naga Chalasani, Robert J. Fontana, Jens C. Goepfert, Frances Hackman, Nicholas M. P. King, Simon Kirby, Patrick Kirby, John Marcinak, Sif Ormarsdottir, Shelli J. Schomaker, Ina Schuppe‐Koistinen, Francis Wolenski, Nadir Arber, Michael Merz, John‐Michael Sauer, Raul J. Andrade, Florian van Bömmel, Thierry Poynard, Paul B. Watkins – 22 January 2018 – Current blood biomarkers are suboptimal in detecting drug‐induced liver injury (DILI) and predicting its outcome.

Xiaolei Wang, Heng Du, Shanshan Shao, Tao Bo, Chunxiao Yu, Wenbin Chen, Lifang Zhao, Qiu Li, Li Wang, Xiaojing Liu, Xiaohui Su, Mingqi Sun, Yongfeng Song, Ling Gao, Jiajun Zhao – 21 January 2018 – Physiological opening of the mitochondrial permeability transition pore (mPTP) is indispensable for maintaining mitochondrial function and cell homeostasis, but the role of the mPTP and its initial factor, cyclophilin D (CypD), in hepatic steatosis is unclear. Here, we demonstrate that excess mPTP opening is mediated by an increase of CypD expression induced hepatic mitochondrial dysfunction.

Xin Wang, Minmin Zhang, Fangfang Ping, Hongchun Liu, Jingya Sun, Yueqin Wang, Aijun Shen, Jian Ding, Meiyu Geng – 21 January 2018 – Though kinase inhibitors have been heavily investigated in the clinic to combat advanced hepatocellular carcinoma (HCC), clinical outcomes have been disappointing overall, which may be due to the absence of kinase‐addicted subsets in HCC patients. Recently, strategies that simultaneously inhibit multiple kinases are increasingly appreciated in HCC treatment, yet they are challenged by the dynamic nature of the kinase networks.

Gin‐Ho Lo – 21 January 2018

Cyrielle Caussy, Scott B. Reeder, Claude B. Sirlin, Rohit Loomba – 21 January 2018 – Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide, and the progressive form of this condition, nonalcoholic steatohepatitis (NASH), has become one of the leading indications for liver transplantation. Despite intensive investigations, there are currently no United States Food and Drug Administration–approved therapies for treating NASH.

Meng Lu, Jiao Wu, Zhi‐Wei Hao, Yu‐Kui Shang, Jing Xu, Gang Nan, Xia Li, Zhi‐Nan Chen, Huijie Bian – 21 January 2018 – Hepatocytes are epithelial cells with highly specialized polarity. The disorder and loss of hepatocyte polarity leads to a weakness of cell adhesion and connection, the induction of epithelial–mesenchymal transition, and eventually the occurrence of hepatocellular carcinoma (HCC). Cluster of differentiation 147 (CD147), a tumor‐related glycoprotein, promotes epithelial–mesenchymal transition and the invasion of HCC.

Minjong Lee, Jeong‐Hoon Lee – 21 January 2018

Charlotte A. Lee, Anil Dhawan, Valeria Iansante, Sharon Lehec, Shirin E. Khorsandi, Celine Filippi, Simon Walker, Raquel Fernandez‐Dacosta, Nigel Heaton, Sanjay Bansal, Ragai R. Mitry, Emer Fitzpatrick – 21 January 2018 – Neonatal livers are a potential source of good‐quality hepatocytes for clinical transplantation. We compared viability and function of neonatal hepatocytes (NHs) and adult hepatocytes (AHs) and report their clinical use both intraportally and in alginate microbeads.

Mercedes Fernandez – 21 January 2018

Cyrielle Caussy, Scott B. Reeder, Claude B. Sirlin, Rohit Loomba – 21 January 2018 – Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease worldwide, and the progressive form of this condition, nonalcoholic steatohepatitis (NASH), has become one of the leading indications for liver transplantation. Despite intensive investigations, there are currently no United States Food and Drug Administration–approved therapies for treating NASH.